Labcorp Holdings annual debt-to-ebitda ratio
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Labcorp Holdings Debt-to-EBITDA Ratio Growth & History (LH)
Labcorp Holdings's debt-to-ebitda ratio was 3.16 for fiscal 2025.
View full Labcorp Holdings company overviewLabcorp Holdings annual debt-to-ebitda ratio history
| Fiscal year | Period ended | Debt-to-EBITDA ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 3.16 | −1.04 | −24.85% |
| 2024 | 2024-12-31 | 4.20 | −0.37 | −8.02% |
| 2023 | 2023-12-31 | 4.57 | 1.41 | +44.40% |
| 2022 | 2022-12-31 | 3.16 | 1.42 | +80.91% |
| 2021 | 2021-12-31 | 1.75 | −0.45 | −20.51% |
| 2020 | 2020-12-31 | 2.20 | −1.53 | −40.94% |
| 2019 | 2019-12-31 | 3.73 | 0.48 | +14.76% |
| 2018 | 2018-12-31 | 3.25 | −0.49 | −13.14% |
| 2017 | 2017-12-31 | 3.74 | 0.37 | +10.98% |
| 2016 | 2016-12-31 | 3.37 | −1.08 | −24.26% |
| 2015 | 2015-12-31 | 4.45 | 1.77 | +66.06% |
| 2014 | 2014-12-31 | 2.68 | 0.20 | +7.93% |
| 2013 | 2013-12-31 | 2.48 | 0.36 | +17.13% |
| 2012 | 2012-12-31 | 2.12 | 0.24 | +12.53% |
| 2011 | 2011-12-31 | 1.88 | 0.03 | +1.71% |
| 2010 | 2010-12-31 | 1.85 | 0.62 | +50.12% |
| 2009 | 2009-12-31 | 1.23 | −0.45 | −26.76% |
| 2008 | 2008-12-31 | 1.68 | — | — |
Labcorp Holdings quarterly debt-to-ebitda ratio
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-EBITDA ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 3.09 | −0.16 | −5.07% |
| Q1 2026 | 2026-03-31 | 3.40 | −0.33 | −8.77% |
| Q4 2025 | 2025-12-31 | 3.16 | −1.04 | −24.85% |
| Q3 2025 | 2025-09-30 | 3.00 | −1.63 | −35.19% |
| Q2 2025 | 2025-06-30 | 3.25 | 0.32 | +10.87% |
| Q1 2025 | 2025-03-31 | 3.73 | 0.73 | +24.17% |
| Q4 2024 | 2024-12-31 | 4.20 | −0.37 | −8.02% |
| Q3 2024 | 2024-09-30 | 4.62 | 0.68 | +17.39% |
| Q2 2024 | 2024-06-30 | 2.93 | −1.10 | −27.30% |
| Q1 2024 | 2024-03-31 | 3.01 | −0.75 | −19.92% |
| Q4 2023 | 2023-12-31 | 4.57 | 1.41 | +44.40% |
| Q3 2023 | 2023-09-30 | 3.94 | 1.37 | +53.11% |
| Q2 2023 | 2023-06-30 | 4.03 | 1.84 | +84.05% |
| Q1 2023 | 2023-03-31 | 3.75 | 1.81 | +92.89% |
| Q4 2022 | 2022-12-31 | 3.16 | 1.42 | +80.91% |
| Q3 2022 | 2022-09-30 | 2.57 | 1.18 | +85.33% |
| Q2 2022 | 2022-06-30 | 2.19 | 0.87 | +65.79% |
| Q1 2022 | 2022-03-31 | 1.95 | 0.60 | +44.77% |
| Q4 2021 | 2021-12-31 | 1.75 | −0.45 | −20.51% |
| Q3 2021 | 2021-09-30 | 1.39 | −1.82 | −56.70% |
| Q2 2021 | 2021-06-30 | 1.32 | −3.87 | −74.55% |
| Q1 2021 | 2021-03-31 | 1.34 | −3.72 | −73.46% |
| Q4 2020 | 2020-12-31 | 2.20 | −1.53 | −40.94% |
| Q3 2020 | 2020-09-30 | 3.21 | −0.79 | −19.82% |
| Q2 2020 | 2020-06-30 | 5.19 | 1.14 | +28.17% |
| Q1 2020 | 2020-03-31 | 5.06 | 1.44 | +39.83% |
| Q4 2019 | 2019-12-31 | 3.73 | 0.48 | +14.76% |
| Q3 2019 | 2019-09-30 | 4.00 | 0.58 | +16.93% |
| Q2 2019 | 2019-06-30 | 4.05 | 0.60 | +17.54% |
| Q1 2019 | 2019-03-31 | 3.62 | −0.10 | −2.58% |
| Q4 2018 | 2018-12-31 | 3.25 | −0.49 | −13.14% |
| Q3 2018 | 2018-09-30 | 3.42 | −0.69 | −16.73% |
| Q2 2018 | 2018-06-30 | 3.45 | −0.07 | −1.99% |
| Q1 2018 | 2018-03-31 | 3.72 | 0.38 | +11.44% |
| Q4 2017 | 2017-12-31 | 3.74 | 0.37 | +10.98% |
| Q3 2017 | 2017-09-30 | 4.11 | 0.45 | +12.43% |
| Q2 2017 | 2017-06-30 | 3.52 | −0.10 | −2.82% |
| Q1 2017 | 2017-03-31 | 3.34 | −0.60 | −15.29% |
| Q4 2016 | 2016-12-31 | 3.37 | −1.08 | −24.26% |
| Q3 2016 | 2016-09-30 | 3.65 | — | — |
| Q2 2016 | 2016-06-30 | 3.62 | — | — |
| Q1 2016 | 2016-03-31 | 3.94 | — | — |
| Q4 2015 | 2015-12-31 | 4.45 | — | — |
| Q1 2014 | 2014-03-31 | 1.47 | −0.42 | −22.16% |
| Q4 2013 | 2013-12-31 | 2.48 | 0.36 | +17.13% |
| Q3 2013 | 2013-09-30 | 2.18 | 0.11 | +5.31% |
| Q2 2013 | 2013-06-30 | 2.06 | 0.41 | +24.55% |
| Q1 2013 | 2013-03-31 | 1.89 | 0.17 | +9.74% |
| Q4 2012 | 2012-12-31 | 2.12 | 0.24 | +12.53% |
| Q3 2012 | 2012-09-30 | 2.07 | 0.37 | +21.81% |
| Q2 2012 | 2012-06-30 | 1.65 | −0.08 | −4.85% |
| Q1 2012 | 2012-03-31 | 1.73 | −0.12 | −6.72% |
| Q4 2011 | 2011-12-31 | 1.88 | 0.03 | +1.71% |
| Q3 2011 | 2011-09-30 | 1.70 | 0.54 | +46.12% |
| Q2 2011 | 2011-06-30 | 1.73 | 0.59 | +51.42% |
| Q1 2011 | 2011-03-31 | 1.85 | 0.67 | +56.97% |
| Q4 2010 | 2010-12-31 | 1.85 | 0.62 | +50.12% |
| Q3 2010 | 2010-09-30 | 1.16 | — | — |
| Q2 2010 | 2010-06-30 | 1.15 | — | — |
| Q1 2010 | 2010-03-31 | 1.18 | — | — |
| Q4 2009 | 2009-12-31 | 1.23 | — | — |
Labcorp Holdings debt-to-ebitda ratio trends
Over the last five fiscal years, Labcorp Holdings's debt-to-ebitda ratio increased from 2.20 to 3.16, a change of 0.96. The latest reported quarter, Q2 2026, shows 3.09.
About the metric
What the debt-to-EBITDA ratio means
Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.
Calculation and source
How debt-to-EBITDA is calculated
TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Labcorp Holdings source filings ↗Community posts
Labcorp sets new medium-term growth targets and reaffirms its annual outlook
Labcorp ($LH) set medium-term targets for annual revenue growth of 5–8% and adjusted earnings-per-share growth of 8.5–11.5% through 2029. The company also reaffirmed its existing 2026 guidance. The new framework describes the performance ma ...
Labcorp acquires MLM Medical Labs to expand clinical-trial services
Labcorp ($LH) acquired MLM Medical Labs, adding central and specialty laboratory operations in the United States, Germany and South Africa. The company said the purchase expands its biomarker-testing capabilities and improves its ability to ...